Affecting the nervous system, immune system and other body organs, ataxia telangiectasia is characterized with uncoordinated movements of the individual suffering from this disorder. The secondary ...

IMMUNOLOGIC abnormalities, including hypogammaglobulinemia, abnormalities of gamma 1 A globulin, poor homograft rejection and structural abnormalities of the thymus gland, have recently been reported ...

Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...

Ataxia-Telangiectasia (A-T) is a rare, inherited, progressive neurodegenerative disorder that typically begins in early childhood. A-T is characterized by degeneration of the cerebellum, leading to ...

New research lends insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia. Ataxia telangiectasia (A-T) is a rare, genetic immunodeficiency disease that affects multiple organ ...

SOUTH SAN FRANCISCO, Calif., October 09, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology ...

A-T (ataxia telangiectasia) is an autosomal recessive genetic disease caused by mutations in the ATM gene 1,2,3,4. Clinically, A-T patients are characterized by progressive childhood cerebellar ataxia ...

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study We identified 421 ...

Should We Screen for Malignancies in People With ataxia telangiectasia? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

SOUTH SAN FRANCISCO, Calif., January 28, 2026--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology ...